JPH0128777B2 - - Google Patents
Info
- Publication number
- JPH0128777B2 JPH0128777B2 JP56180681A JP18068181A JPH0128777B2 JP H0128777 B2 JPH0128777 B2 JP H0128777B2 JP 56180681 A JP56180681 A JP 56180681A JP 18068181 A JP18068181 A JP 18068181A JP H0128777 B2 JPH0128777 B2 JP H0128777B2
- Authority
- JP
- Japan
- Prior art keywords
- component
- weight
- resin composition
- maleic anhydride
- examples
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000011342 resin composition Substances 0.000 claims description 22
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 21
- 229920001577 copolymer Polymers 0.000 claims description 17
- 239000000178 monomer Substances 0.000 claims description 15
- 125000001931 aliphatic group Chemical group 0.000 claims description 7
- 229920002554 vinyl polymer Polymers 0.000 claims description 6
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims description 5
- 150000001336 alkenes Chemical class 0.000 claims description 4
- 229920001567 vinyl ester resin Polymers 0.000 claims description 4
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 17
- 239000013543 active substance Substances 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 238000002156 mixing Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 10
- 238000007334 copolymerization reaction Methods 0.000 description 8
- JJCQSGDBDPYCEO-XVZSLQNASA-N dibekacin Chemical compound O1[C@H](CN)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N JJCQSGDBDPYCEO-XVZSLQNASA-N 0.000 description 7
- -1 phosphonic groups Chemical group 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical compound CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010093965 Polymyxin B Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- 230000003100 immobilizing effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960005356 urokinase Drugs 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 210000000476 body water Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 229960003548 polymyxin b sulfate Drugs 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- NYEPHMYJRNWPLA-UHFFFAOYSA-N (6-amino-2-ethoxyacridin-9-yl)azanium;2-hydroxypropanoate;hydrate Chemical compound O.CC(O)C([O-])=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3[NH+]=C21 NYEPHMYJRNWPLA-UHFFFAOYSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- FPSURBCYSCOZSE-UHFFFAOYSA-N 1-ethenoxybutan-1-ol Chemical compound CCCC(O)OC=C FPSURBCYSCOZSE-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- ULGJWNIHLSLQPZ-UHFFFAOYSA-N 7-[(6,8-dichloro-1,2,3,4-tetrahydroacridin-9-yl)amino]-n-[2-(1h-indol-3-yl)ethyl]heptanamide Chemical compound C1CCCC2=NC3=CC(Cl)=CC(Cl)=C3C(NCCCCCCC(=O)NCCC=3C4=CC=CC=C4NC=3)=C21 ULGJWNIHLSLQPZ-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000005263 alkylenediamine group Chemical group 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 108010003977 aminoacylase I Proteins 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960003807 dibekacin Drugs 0.000 description 1
- 238000000578 dry spinning Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 108010093305 exopolygalacturonase Proteins 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine group Chemical group P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001228 polyisocyanate Polymers 0.000 description 1
- 239000005056 polyisocyanate Substances 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Landscapes
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Description
本発明は新規な樹脂組成物に関するものであり
さらに詳しくは、(A)無水マレイン酸とそれと共重
合し得る脂肪族ビニルエーテルまたは脂肪族ビニ
ルエステルとの共重合体〔以下(A)成分と略記す
る。〕と(B)無水マレイン酸とそれと共重合し得る
芳香族ビニルモノマーまたはオレフインモノマー
との共重合体〔以下(B)成分と略記する。〕とから
なる樹脂組成物に関するものである。
(A)成分は古くから知られており、種々の共重合
成分、共重合形態(ブロツク、ランダムなど)、
共重合比を有するものが合成されている。例えば
無水マレイン酸とメチルビニルエーテルの共重合
比1:1のブロツク共重合体などが工業的に生産
されている。このような(A)成分は水、有機溶媒へ
の溶解性に優れ、また例えば樹脂、可塑剤、金属
塩との融和性に優れ、良好な成形性、高い反応性
などを有しており種々の用途に利用されている。
なかでもその高い反応性を利用して、生理活性物
質を固化する担体に使用した場合の利点は多い。
従来から生理活性物質を担体に固定化して不溶
化し、活性を安定化したり、持続させたりあるい
は利用し易くする試みが多くなされているがこの
ような試みに際しては、適切な固定化方法を採用
し、適切な担体を使用することが、生理活性物質
の諸活性を有効に作用させるうえで大切なことで
ある。
固定化の方法としては、従来から生理活性物質
を溶液状態にしてこの溶液を担体にスプレーする
方法、この溶液に担体を浸漬する方法などが取ら
れており、特に後者の方法が簡便且確実であるた
め圧倒的に多く採用されている。そして、この場
合の溶剤としてはほとんどの場合に水が使用され
ている。希にアルコールその他の有機溶剤が使用
される特殊な場合があるが、生理活性物質の活性
を落さないことが非常に大切なことであるので水
以外の溶剤を使用するのは好ましくない場合が多
い。
従つて、固定化用の担体としては、次のような
機能が要求される。すなわち固定化反応を行う
ために必要なだけの時間は耐水性を持つこと、
固定化された担体は水、体液、血液などと接触す
る場において使用されることが多いので、そのよ
うな場において長時間耐水性を保持すること、
生理活性物質を固定化し得る能力の高いこと、
固定化反応において、生理活性物質の活性が失な
われる程の高温を必要としないこと、フイル
ム、糸状物、顆粒などが種々の形状の成形品が得
られることなどがあげられる。
(A)成分は生理活性物質固定化用の担体として機
能〜を充分に満足する。このことは、従来か
らの代表的な担体である活性化セフアデツクス、
活性化ガラスビーズ、活性炭素などが成形不可能
であり、例えば顆粒状あるいはゲル状などの定ま
つた形状のものしか得られず、使用の場に大きな
制限があることと比べれば、優良な担体であるこ
とを意味する。しかしながら(A)成分は耐水性に問
題があり、常に水分、体液、血液などと接触して
いる場においての使用は不可能であるばかりでな
く、生理活性物質の固定化に最低限必要とされる
時間、すなわち5〜10分程度の短い時間における
耐水性にも問題があり、生理活性物質の水溶液に
担体を浸漬して固定化を行うといつた通常の固定
化操作を取ることもできない。(A)成分を使用した
場合に生じる上記の問題を解決する方法として
は、
(1) (A)成分にこれと架橋反応を起すことが可能な
多官能性化合物を配合し、加熱処理を施こすな
どして(A)成分同志を架橋させて耐水性を付与す
る。
(2) (A)成分に、他の疎水性の高いポリマーを配合
し耐水性を付与する。
等の方法が考えられる。
(1)の方法としては、多くの方法が公知であるが
例えば米国特許第3810468号明細書などに公示さ
れているごとくにグリコールやアルキレンジアミ
ンを架橋剤として使用した場合には、得られる成
形品は硬くてもろく、このものを担体としてカラ
ム充てん剤、フイルターなどとして用いることは
不可能である。また一般に、このような架橋反応
に関しては機能を満足するように行なえば機能
が減少するといつた新たな問題が発生する。
(2)の方法は、従来より着目されていない方法で
ある。本発明者らは、(A)成分に他のポリマーを配
合する方法に着目し、(A)成分のもつ担体としての
すぐれた機能を低下させることなく耐水性が改良
された樹脂組成物を得るべく(A)成分と種々のポリ
マーとの配合系について鋭意研究を行つた。
すなわち、無水マレイン酸以外の酸以外の酸性
基、例えばカルボキシル基、スルホン基、ホスホ
ン基、ホスフイン基、フエノール性水酸基などを
有するモノマーよりのホモポリマーおよびこれら
のモノマーと共重合可能な他のモノマーとの共重
合体などのポリマーを選びこれらのポリマーを(A)
成分に配合して、相溶性、組成物の安定性、生理
活性物質固定化用担体としての適応性について調
べたところ、いくつかのポリマーでは(A)成分との
相溶性が悪く、両者を混合するだけで凝集が生じ
均一に混合することすら難しく、またたとえ外観
上均一に混合したように見えるものであつても、
その組成物より流延法によつてフイルムを作成す
ると層分離を起したりする場合が多かつた。また
均一に混合可能な場合でも固定化能力が大巾は減
少したり、成形性が悪くなることを認めたが驚く
べきことに、無水マレイン酸とそれと共重合し得
る芳香族ビニルモノマーまたはオレフインモノマ
ーの共重合体を(A)成分に配合してなる組成物のみ
が(A)成分のもつ担体として長所を損わずにその耐
水性を改良しうることを見出し、本発明に到達し
た。
すなわち本発明は、(A)無水マレイン酸とそれと
共重合し得る脂肪族ビニルエーテルまたは脂肪族
ビニルエステルとの共重合体0.5〜99.5重量部と
(B)無水マレイン酸とそれと共重合し得る芳香族ビ
ニルモノマーまたはオレフインモノマーとの共重
合体0.5〜99.5重量部とからなる樹脂組成物であ
る。
本発明の樹脂組成物は均一であり、フイルムに
しても層分離を起さずかつ長期間安定である。
本発明の(B)成分としては、無水マレイン酸とそ
れと共重合し得る芳香族ビニルモノマーまたはオ
レフイン化合物との共重合体であればいかなる共
重合体でも使用可能であるが、好ましくは無水マ
レイン酸とスチレンまたはエチレンまたはイソブ
チレンまたはポリプロピレンとの共重合体が使用
され、特に好ましくは無水マレイン酸と上記のモ
ノマーとの共重合体で、共重合比が1:1〜1:
5であり分子量が500〜2000000のものが使用され
る。
不発明の(A)成分としては、無水マレイン酸とそ
れと共重合し得る脂肪族ビニルモノマーまたは脂
肪族ビニルエステルとの共重合体であればいかな
る共重合体でも使用可能であるが、好ましくは無
水マレイン酸と酢酸ビニルまたはメチルビニルエ
ーテルまたはエチルビニルエーテルまたはブタン
ジオールビニルエーテルとの共重合体が使用さ
れ、特に好ましくは無水マレイン酸と上記のモノ
マーとの共重合体で、共重合比が1:1〜1:5
であり分子量が500〜2000000のものが使用され
る。
本発明の樹脂組成物において、(A)成分と(B)成分
の合計量に対する(A)成分が0.5重量%未満である
と成形性、被膜形成性、曳糸性が著しく悪くなり
また生理活性物質を固定化する能力も減少し、一
方、99.5重量%をこえると耐水性が極端に悪くな
り、例えばこのものから得られるフイルムを水中
に浸漬すると数分間で溶解を始め形状がくずれ始
める。従つてこのものに生理活性物質水溶液を接
触させて固定化を行うことは不可能である。より
充分な耐水性を与えひいては常に水、血液体液な
どと常に接触するごとくの場での使用にたえるご
とくにするには、(A)成分は好ましくは80重量%以
下、さらに好ましくは70重量%以下の量配合され
るのが望ましい。また、より十分な成形性、被膜
形成性、曳糸性及び生理活性物質固定化能力を持
つごとくにするには、(A)成分は好ましくは1重量
%以上、さらに好ましくは3重量%以上、特に好
ましくは5重量%以上、最も好ましくは10重量%
以上の量配合されるのが望ましい。したがつて、
(A)成分としては好ましくは1〜80重量%、特に好
ましくは5〜80重量%、最も好ましくは10〜70重
量%の範囲で配合されるのが望ましいが、特に耐
水性が重要視される場合には好ましくは1〜10重
量%、特に好ましくは3〜10重量%の範囲で配合
されるのが望ましく、特に成形性、被膜形成性、
曳糸性及び生理活性物質固定化能力が重要視され
る場合には50〜80重量%の範囲で配合されるのが
望ましい。
本発明の樹脂組成物は、例えば有機溶剤を媒体
として(A)成分と(B)成分を混合することにより調製
することができる。すなわち、(A)成分の溶液と(B)
成分の溶液を混合する方法、(A)成分の溶液に(B)成
分を添加して混合する方法、(B)成分の溶液に(A)成
分を添加して混合する方法、(A)成分と(B)成分に溶
剤を加えて混合する方法などにより調製すること
ができる。そして混合効果を高め混合時間を短か
くするためには、必要に応じて加熱したり、撹拌
するのが望ましい。本発明の樹脂組成物を製造す
る際に使用可能な有機溶剤としては例えばアセト
ン、メチルエチルケトンなどのケトン類、ベンズ
アルデヒド、ホルムアルデヒド、ジメチルホルム
アルデヒドなどのアルデヒド類、テトラヒドロフ
ランなどのエーテル類、酢酸メチル、酢酸エチル
などのエステル類、メタノール、エタノール、プ
ロパノール、イソプロパノール、ブタノールなど
のアルコール類などがあげられるが好ましくはケ
トン類、アルコール類が用いられる。このように
して有機溶剤を媒体として調製した本発明の樹脂
組成物からは、加熱などにより溶剤を気化させる
と固体状の樹脂組成物が得られ、特にフイルムや
シート状物、糸状物に成形された固体状の樹脂組
成物を容易に得ることができる。
本発明の樹脂組成物は、実施例に示したように
(A)成分単独の場合と比較して耐水性に優れ、かつ
生理活性物質を固定化する能力が、(A)成分と(B)成
分を混合した時に期待し得る能力にはるかに上廻
つている。
従つて本発明の樹脂組成物は、その高い反応性
良好な成形性および耐水性の故に広範囲の分野に
利用することができるが、なかでも各種生理活性
物質を固定化する担体として特に好ましく利用す
ることができる。ここにいう生理活性物質とは、
生体に何らかの薬理的効果、生理的影響を与える
物質を意味し、より具体的には例えば、アミラー
ゼ、トリプシン、キモトリプシン、アミノアシラ
ーゼ、ガラクトシターゼ、インベルターゼ、ペク
チナーゼ、L−アスパラギナーゼ、グルコースオ
シキターゼ、ウリアーゼ、セルラーゼ、などの諸
酵素、各種抗原、抗体、酵素阻害剤、各種ホルモ
ン、補酵素、各種制ガン剤、抗ガン剤、アミカシ
ン、ジベカシン、カナマイシン、ストレプトマイ
シン、ゲンタマイシン、フラジオマイシン、ポリ
ミキシンなどの抗生物質、アクリノール、アクリ
ルフラビン、塩化ベンザルコニウム、塩化ベンゼ
トニウム、シクロヘキシジンなどの殺菌剤などの
各種薬剤などが挙げられるが、諸酵素、抗原、抗
体、抗生物質、殺菌剤などが本発明の樹脂組成物
に好ましく固定化される。
本発明の樹脂組成物には必要に応じて他の成分
を混合することができる。そのような成分として
は、本発明に用いられる(A)成分または(B)成分と架
橋反応を起すことのできる架橋剤がその代表的な
例である。
本発明の樹脂組成物に他の成分を混合させる方
法は、本発明の樹脂組成物を調製する方法に準じ
て行うことができ、(A)成分と(B)成分と他の成分を
混合する順序は任意である。
本発明の樹脂組成物に混合しうる架橋剤として
は、例えば、ヘキサメチレンジイソシアナート、
トルエンジイソシアナートなどのポリイソシアナ
ート、ポリビニルアルコールおよびその誘導体、
エチレングリコール、プロピレングリコール、ブ
チレングリコール、ポリエチレングリコールなど
のポリオール、でんぷん、ゼラチン、デキストラ
ンなどの天然高分子、ヘキサメチレンジアミン、
エチレンジアミン、トリメチレンジアミン、など
のポリアミン、モノエタノールアミン、トリエタ
ノールアミンなどのアミノアルコールなどが挙げ
られるが、ポリビニルアルコール、ポリオールな
どが好ましく用いられる。
以下に実施例を挙げて本発明をさらに具体的に
詳明する。なお、例中の「部」は「重量部」を意
味する。
実施例1〜5、比較例1〜2
Gantrez AN169(GAF社製、無水マレイン酸
とメチルビニルエーテルとの共重合体)の10重量
%アセトン溶液と、SMA3000(ARCO Chemical
社製、無水マレイン酸とスチレンとの共重合体)
の10重量%アセトン溶液を作成し、両溶液を混合
してGantrez 169とSMA3000の固形分の重量比
が5/95、20/80、50/50、80/20、95/5にな
るように調整した。このようにして調整した樹脂
組成物は35℃で1カ月放置しても透明で相分離せ
ず安定であつた。この樹脂組成物をポリエステル
フイルム上に流延し、100℃にて熱風乾燥して厚
さ50μのフイルムを作成した。
比較のため、Gantrez 169とSMA3000の固形
分の重量比が100/0、99.7/0.3、0.3/99.7、
0/100となるように調整したアセトン溶液と同
様にして流延し乾燥した。
実施例1〜5および比較例1〜4の被膜形成性
およびこれらのフイルムを25℃の水に浸漬して観
察した耐水性は表1に示すとおりであつた。
The present invention relates to a novel resin composition, and more particularly, it relates to a copolymer of (A) maleic anhydride and an aliphatic vinyl ether or aliphatic vinyl ester copolymerizable therewith [hereinafter abbreviated as component (A)]. . ] and (B) a copolymer of maleic anhydride and an aromatic vinyl monomer or olefin monomer copolymerizable therewith [hereinafter abbreviated as component (B). ] This relates to a resin composition consisting of the following. Component (A) has been known for a long time, and includes various copolymerization components, copolymerization forms (block, random, etc.),
Those having a copolymerization ratio have been synthesized. For example, block copolymers of maleic anhydride and methyl vinyl ether in a copolymerization ratio of 1:1 are industrially produced. Component (A) has excellent solubility in water and organic solvents, excellent compatibility with resins, plasticizers, and metal salts, good moldability, high reactivity, etc., and is used in a variety of applications. It is used for this purpose.
Among these, there are many advantages when using it as a carrier for solidifying physiologically active substances by taking advantage of its high reactivity. In the past, many attempts have been made to immobilize physiologically active substances on carriers and make them insoluble, thereby stabilizing or sustaining their activity or making them easier to use. It is important to use an appropriate carrier in order to effectively exert the various activities of a physiologically active substance. Conventional methods for immobilization include preparing a physiologically active substance in a solution state and spraying this solution onto a carrier, and immersing the carrier in this solution.The latter method is particularly simple and reliable. Because of this, it is overwhelmingly adopted. In most cases, water is used as the solvent. Although there are rare special cases where alcohol or other organic solvents are used, it is extremely important not to reduce the activity of physiologically active substances, so it may not be preferable to use solvents other than water. many. Therefore, a carrier for immobilization is required to have the following functions. In other words, it must be water resistant for the time necessary to carry out the immobilization reaction;
Immobilized carriers are often used in places where they come into contact with water, body fluids, blood, etc., so they must maintain water resistance for a long time in such places.
High ability to immobilize physiologically active substances,
The immobilization reaction does not require high temperatures to the extent that the activity of the physiologically active substance is lost, and molded products of various shapes such as films, filaments, and granules can be obtained. Component (A) fully satisfies the function of a carrier for immobilizing a physiologically active substance. This indicates that activated cephadex, which is a typical conventional carrier,
Compared to activated glass beads, activated carbon, etc., which cannot be molded and can only be obtained in fixed shapes, such as granules or gels, there are major limitations on where they can be used. It means that. However, component (A) has problems with water resistance, and not only is it impossible to use in areas where it is constantly in contact with water, body fluids, blood, etc. There is also a problem with water resistance over a short period of time, i.e., about 5 to 10 minutes, and normal immobilization operations such as immobilization by immersing the carrier in an aqueous solution of a physiologically active substance cannot be used. As a method to solve the above problems that occur when using component (A), (1) a polyfunctional compound that can cause a crosslinking reaction with component (A) is blended, and heat treatment is performed. By rubbing, etc., component (A) crosslinks with each other to impart water resistance. (2) Component (A) is blended with other highly hydrophobic polymers to impart water resistance. Possible methods include: Many methods are known for method (1), but when glycol or alkylene diamine is used as a crosslinking agent, as disclosed in U.S. Pat. No. 3,810,468, the molded product obtained is hard and brittle, making it impossible to use it as a carrier, column packing material, filter, etc. Furthermore, in general, new problems arise with such crosslinking reactions, such as a decrease in functionality if the reaction is carried out in a manner that satisfies the functionality. Method (2) is a method that has not received much attention in the past. The present inventors focused on a method of blending other polymers with component (A), and obtained a resin composition with improved water resistance without reducing the excellent function of component (A) as a carrier. In order to achieve this goal, we conducted intensive research on the blending system of component (A) and various polymers. That is, homopolymers made of monomers having acidic groups other than acids other than maleic anhydride, such as carboxyl groups, sulfone groups, phosphonic groups, phosphine groups, and phenolic hydroxyl groups, and other monomers copolymerizable with these monomers. Select polymers such as copolymers of (A)
When we investigated the compatibility, stability of the composition, and suitability as a carrier for immobilizing physiologically active substances, we found that some polymers had poor compatibility with component (A), making it difficult to mix the two. It is difficult to even mix uniformly because agglomeration occurs just by mixing, and even if it looks like it is mixed uniformly,
When a film is made from this composition by a casting method, layer separation often occurs. It was also found that even when homogeneous mixing was possible, the immobilization ability was significantly reduced and the moldability deteriorated, but surprisingly, maleic anhydride and aromatic vinyl monomers or olefin monomers that can be copolymerized with maleic anhydride. The inventors have discovered that only a composition containing a copolymer of (A) and (A) can improve the water resistance of component (A) without impairing its advantages as a carrier, and has thus arrived at the present invention. That is, the present invention comprises (A) 0.5 to 99.5 parts by weight of a copolymer of maleic anhydride and an aliphatic vinyl ether or aliphatic vinyl ester that can be copolymerized therewith;
(B) A resin composition comprising 0.5 to 99.5 parts by weight of a copolymer of maleic anhydride and an aromatic vinyl monomer or olefin monomer copolymerizable with maleic anhydride. The resin composition of the present invention is uniform, does not cause layer separation even when made into a film, and is stable for a long period of time. As component (B) of the present invention, any copolymer of maleic anhydride and an aromatic vinyl monomer or olefin compound that can be copolymerized therewith can be used, but maleic anhydride is preferable. and styrene or ethylene or isobutylene or polypropylene are used, particularly preferably copolymers of maleic anhydride and the abovementioned monomers, in a copolymerization ratio of 1:1 to 1:
5 and a molecular weight of 500 to 2,000,000 is used. As the uninvented component (A), any copolymer of maleic anhydride and an aliphatic vinyl monomer or aliphatic vinyl ester that can be copolymerized with maleic acid can be used, but anhydrous maleic anhydride is preferably used. Copolymers of maleic acid and vinyl acetate or methyl vinyl ether or ethyl vinyl ether or butanediol vinyl ether are used, particularly preferably copolymers of maleic anhydride and the monomers mentioned above, in a copolymerization ratio of 1:1 to 1. :5
and those with a molecular weight of 500 to 2,000,000 are used. In the resin composition of the present invention, if the amount of component (A) is less than 0.5% by weight based on the total amount of components (A) and (B), the moldability, film-forming property, and stringiness will be significantly deteriorated, and the physiological activity The ability to immobilize substances also decreases, and on the other hand, if it exceeds 99.5% by weight, water resistance becomes extremely poor.For example, when a film obtained from this material is immersed in water, it begins to dissolve and lose its shape within a few minutes. Therefore, it is impossible to immobilize this material by contacting it with an aqueous solution of a physiologically active substance. In order to provide more sufficient water resistance and to be suitable for use in places where there is constant contact with water, blood, body fluids, etc., component (A) is preferably 80% by weight or less, and more preferably 70% by weight. % or less is desirable. In addition, in order to have more sufficient moldability, film-forming properties, stringinability, and ability to immobilize physiologically active substances, component (A) is preferably 1% by weight or more, more preferably 3% by weight or more, Particularly preferably 5% by weight or more, most preferably 10% by weight
It is desirable that the above amount is blended. Therefore,
Component (A) is preferably blended in an amount of 1 to 80% by weight, particularly preferably 5 to 80% by weight, most preferably 10 to 70% by weight, but water resistance is particularly important. In this case, it is preferably blended in an amount of 1 to 10% by weight, particularly preferably 3 to 10% by weight, and particularly improves moldability, film-forming properties,
When stringability and the ability to immobilize physiologically active substances are important, it is desirable that the content be in the range of 50 to 80% by weight. The resin composition of the present invention can be prepared, for example, by mixing components (A) and (B) using an organic solvent as a medium. That is, a solution of (A) component and (B)
Method of mixing component solutions, method of adding (B) component to (A) component solution and mixing, method of adding (A) component to (B) component solution and mixing, (A) component It can be prepared by adding a solvent to component (B) and mixing them. In order to enhance the mixing effect and shorten the mixing time, it is desirable to heat or stir as necessary. Examples of organic solvents that can be used in producing the resin composition of the present invention include ketones such as acetone and methyl ethyl ketone, aldehydes such as benzaldehyde, formaldehyde, and dimethyl formaldehyde, ethers such as tetrahydrofuran, methyl acetate, and ethyl acetate. and alcohols such as methanol, ethanol, propanol, isopropanol, and butanol, but ketones and alcohols are preferably used. From the resin composition of the present invention prepared in this way using an organic solvent as a medium, when the solvent is vaporized by heating etc., a solid resin composition can be obtained, and in particular, it can be formed into a film, sheet-like object, or filament-like object. A solid resin composition can be easily obtained. As shown in the examples, the resin composition of the present invention
It has superior water resistance compared to component (A) alone, and its ability to immobilize physiologically active substances far exceeds the ability expected when components (A) and (B) are mixed. . Therefore, the resin composition of the present invention can be used in a wide range of fields due to its high reactivity, good moldability, and water resistance, but it is particularly preferably used as a carrier for immobilizing various physiologically active substances. be able to. What is the physiologically active substance mentioned here?
It means a substance that has some kind of pharmacological effect or physiological influence on a living body, and more specifically, for example, amylase, trypsin, chymotrypsin, aminoacylase, galactosidase, invertase, pectinase, L-asparaginase, glucose oxidase, uriase. , various enzymes such as cellulase, various antigens, antibodies, enzyme inhibitors, various hormones, coenzymes, various anticancer drugs, anticancer drugs, antibiotics such as amikacin, dibekacin, kanamycin, streptomycin, gentamicin, fradiomycin, polymyxin, acrinol , acrylflavin, benzalkonium chloride, benzethonium chloride, bactericidal agents such as cyclohexidine, etc., and various enzymes, antigens, antibodies, antibiotics, bactericidal agents, etc. are preferably used in the resin composition of the present invention. Fixed. Other components can be mixed into the resin composition of the present invention as needed. A typical example of such a component is a crosslinking agent that can cause a crosslinking reaction with component (A) or component (B) used in the present invention. The method of mixing other components into the resin composition of the present invention can be carried out according to the method of preparing the resin composition of the present invention, and the method of mixing component (A), component (B), and other components can be carried out according to the method of preparing the resin composition of the present invention. The order is arbitrary. Examples of crosslinking agents that can be mixed into the resin composition of the present invention include hexamethylene diisocyanate,
Polyisocyanates such as toluene diisocyanate, polyvinyl alcohol and its derivatives,
Polyols such as ethylene glycol, propylene glycol, butylene glycol, and polyethylene glycol, natural polymers such as starch, gelatin, and dextran, hexamethylene diamine,
Examples include polyamines such as ethylenediamine and trimethylenediamine, and aminoalcohols such as monoethanolamine and triethanolamine, with polyvinyl alcohol, polyols, and the like being preferably used. The present invention will be explained in more detail with reference to Examples below. Note that "parts" in the examples mean "parts by weight." Examples 1 to 5, Comparative Examples 1 to 2 A 10% by weight acetone solution of Gantrez AN169 (manufactured by GAF, a copolymer of maleic anhydride and methyl vinyl ether) and SMA3000 (ARCO Chemical
Copolymer of maleic anhydride and styrene)
Create a 10% by weight acetone solution of and mix both solutions so that the solid weight ratio of Gantrez 169 and SMA3000 is 5/95, 20/80, 50/50, 80/20, 95/5. It was adjusted. The resin composition thus prepared remained transparent and stable without phase separation even after being left at 35°C for one month. This resin composition was cast onto a polyester film and dried with hot air at 100°C to produce a film with a thickness of 50μ. For comparison, the solid content weight ratios of Gantrez 169 and SMA3000 are 100/0, 99.7/0.3, 0.3/99.7,
It was cast and dried in the same manner as the acetone solution adjusted to 0/100. The film forming properties of Examples 1 to 5 and Comparative Examples 1 to 4 and the water resistance observed by immersing these films in 25°C water are as shown in Table 1.
【表】
実施例1〜5および比較例2〜3で得られたフ
イルム各1gを硫酸ジベカシン水溶液〔50mg(力
価)/100ml〕に25℃にて15分間浸漬させたとこ
ろ実施例1〜5の5枚のフイルムとも35mgの硫酸
ジベカシンを固定化しており、固定化された硫酸
ジベカシンの活性は1カ月経過後も不変であつ
た。比較例2のフイルムについては、浸漬後5分
で形状がくずれだしたためその時点で取り出した
ところ固定化された量は5mgであつた。
比較例3のフイルムについては他の5枚のフイ
ルムと同時点で取り出したが、固定化量は8mgで
あつた。
実施例1〜5で得られたフイルム各1gをヘブ
スブリン(ミドリ十字社製、乾燥抗B型肝炎人免
疫グロブリン)水溶液〔250mg/100ml〕に7℃に
て10時間浸漬させたところ5枚のフイルムとも
100mgのヘブスブリンを固定化した。固定化され
たヘブスブリンの活性は7℃の空気中にて3カ月
保存後も安定であつた。
ヘブスブリン水溶液の代わりにウロキナーゼ水
溶液〔250mg/100ml〕を使用した他は上記の場合
と同様にして実施例1〜5のフイルムを処理した
ところ各々90mgのウロキナーゼを固定化した。固
定化されたウロキナーゼの活性は長期保存されて
いた。
実施例 6〜10
SMA3000の代わりに無水マレイン酸とエチレ
ンの共重合体(共重合比1:1、分子量50万)を
用いた他は実施例1〜5と同様にしてフイルムを
作成した。得られたフイルムについて実施例1〜
5と同様にして硫酸ジベカシンを固定化したとこ
ろ5枚のフイルムとも30mg(力価)の硫酸ジベカ
シンを固定化した。固定化された硫酸ジベカシン
の活性は長期間保持されていた。
実施例 11〜15
Gantrez AN169の代わりに無水マレイン酸と
エチルビニルエーテルの共重合体(共重合比1:
1、分子量50万)を用いた他は実施例1〜5と同
様にしてフイルムを作成した。得られたフイルム
を硫酸ポリミキシンB水溶液〔50万単位/100mg〕
に7℃にて20分浸漬したところ、5枚のフイルム
は35万単位の硫酸ポリミキシンBを固定化した。
固定化した硫酸ポリミキシンBの活性は長期間保
持されていを。
実施例 16
Gantrez AN169 50部とSMA3000 50部を300
部部のアセトンに溶解し、この溶液から乾式紡糸
法により10dの糸を作成した。得られた糸は、実
施例3と同様に優れた耐水性、生理活性物質固定
化能力を有していた。
比較例 3
Gantrez AN169 0.3部とSMA3000 99.7部を
300部のアセトンに溶解し、この溶液を用いて実
施例16と同様の紡糸を試みたが、曳糸性が悪く紡
糸は不可能であつた。[Table] 1 g each of the films obtained in Examples 1 to 5 and Comparative Examples 2 to 3 was immersed in an aqueous dibekacin sulfate solution [50 mg (potency)/100 ml] at 25°C for 15 minutes. All of the five films immobilized 35 mg of dibekacin sulfate, and the activity of the immobilized dibekacin sulfate remained unchanged even after one month had passed. Regarding the film of Comparative Example 2, its shape began to collapse 5 minutes after immersion, and when it was taken out at that point, the amount immobilized was 5 mg. The film of Comparative Example 3 was taken out at the same time as the other five films, and the amount of immobilization was 8 mg. When 1 g of each of the films obtained in Examples 1 to 5 was immersed in an aqueous solution [250 mg/100 ml] of Hebsbrin (manufactured by Midori Juji Co., Ltd., dried anti-hepatitis B human immunoglobulin) at 7°C for 10 hours, 5 films were obtained. friend
100 mg of hebusbrin was immobilized. The activity of immobilized hebusbulin remained stable even after storage for 3 months in air at 7°C. The films of Examples 1 to 5 were treated in the same manner as described above, except that an aqueous urokinase solution [250 mg/100 ml] was used instead of an aqueous hebusbrin solution, and 90 mg of urokinase was immobilized on each film. The activity of immobilized urokinase was conserved over a long period of time. Examples 6 to 10 Films were prepared in the same manner as in Examples 1 to 5, except that a copolymer of maleic anhydride and ethylene (copolymerization ratio 1:1, molecular weight 500,000) was used instead of SMA3000. Examples 1 to 3 about the obtained films
When dibekacin sulfate was immobilized in the same manner as in step 5, 30 mg (titer) of dibekacin sulfate was immobilized on all five films. The activity of immobilized dibekacin sulfate was retained for a long time. Examples 11-15 Instead of Gantrez AN169, a copolymer of maleic anhydride and ethyl vinyl ether (copolymerization ratio 1:
Films were prepared in the same manner as in Examples 1 to 5, except that 1, molecular weight: 500,000) was used. The obtained film was mixed with a sulfuric acid polymyxin B aqueous solution [500,000 units/100mg]
When immersed in water for 20 minutes at 7°C, 350,000 units of polymyxin B sulfate were immobilized on the five films.
The activity of immobilized polymyxin B sulfate is maintained for a long period of time. Example 16 Gantrez AN169 50 parts and SMA3000 50 parts to 300
A 10 d thread was prepared from this solution by a dry spinning method. The obtained thread had excellent water resistance and ability to immobilize physiologically active substances as in Example 3. Comparative example 3 Gantrez AN169 0.3 parts and SMA3000 99.7 parts
It was dissolved in 300 parts of acetone and spinning was attempted in the same manner as in Example 16 using this solution, but spinnability was poor and spinning was impossible.
Claims (1)
族ビニルエーテルまたは脂肪族ビニルエステルと
の共重合体0.5〜99.5重量部と、(B)無水マレイン
酸とそれと共重合し得る芳香族ビニルモノマーま
たはオレフインモノマーとの共重合体0.5〜99.5
重量部とからなる樹脂組成物。1 (A) 0.5 to 99.5 parts by weight of a copolymer of maleic anhydride and an aliphatic vinyl ether or aliphatic vinyl ester copolymerizable therewith; (B) maleic anhydride and an aromatic vinyl monomer copolymerizable therewith; or Copolymer with olefin monomer 0.5-99.5
A resin composition consisting of parts by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56180681A JPS5883041A (en) | 1981-11-10 | 1981-11-10 | Resin composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56180681A JPS5883041A (en) | 1981-11-10 | 1981-11-10 | Resin composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5883041A JPS5883041A (en) | 1983-05-18 |
| JPH0128777B2 true JPH0128777B2 (en) | 1989-06-05 |
Family
ID=16087438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56180681A Granted JPS5883041A (en) | 1981-11-10 | 1981-11-10 | Resin composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5883041A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101864408A (en) * | 2010-05-25 | 2010-10-20 | 中国科学院过程工程研究所 | A kind of preparation method of nanofiber immobilized β-D-galactosidase |
-
1981
- 1981-11-10 JP JP56180681A patent/JPS5883041A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5883041A (en) | 1983-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU649533B2 (en) | Method of preparing microspheres | |
| EP1019446B1 (en) | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor | |
| US5041292A (en) | Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents | |
| US5346935A (en) | Hydrogel | |
| EP0746582B1 (en) | Membrane formed by an acrylonitrile-based polymer | |
| CA1088009A (en) | Immobilized enzymes as well as their production and use | |
| JPH0339087B2 (en) | ||
| JPS6059933B2 (en) | Polymer membrane with maleic anhydride residues | |
| JP3274844B2 (en) | Solvent and acid stable membranes based on copolymers of acrylonitrile and comonomer | |
| JPS59105005A (en) | Vinylene carbonate polymer and its manufacturing method | |
| CA2093826C (en) | Process for preparing optically active cyanohydrins with enzymes | |
| JPH0128777B2 (en) | ||
| US4218363A (en) | Preparation of support matrices for immobilized enzymes | |
| JPH0257580B2 (en) | ||
| EP0596315B1 (en) | A method of attaching dialdehyde starch to a surface and products produced by that method | |
| US4250080A (en) | Preparation of support matrices for immobilized enzymes | |
| JP2853452B2 (en) | Method for producing molded article immobilized with physiologically active substance | |
| CA2146192C (en) | Polyionic insoluble hydrogels comprising xanthan | |
| JP2907492B2 (en) | Heparin sustained release material and method for producing the same | |
| JPH0364144B2 (en) | ||
| SU859372A1 (en) | Method of producing activated supports | |
| JPH0576449B2 (en) | ||
| SU755296A1 (en) | METHOD FOR OBTAINING ACTIVATED MEDIA FOR IMMOBILIZATION OF BIOLOGICALLY ACTIVE SUBSTANCES 1 | |
| JPH0622628B2 (en) | Carrier for immobilization of physiologically active substance and method for producing the same | |
| SU664468A1 (en) | Method of preparing activated supports |